Aug 19, 2026 07:01AM
Aug 19, 2026 07:00AM
Aug 17, 2026 09:15AM
Aug 17, 2026 09:15AM
Jul 28, 2026 07:01AM
Jul 28, 2026 07:00AM
Jul 16, 2026 07:32AM Galmed develops heart-targeted nanoparticle formulation of Aramchol
Jul 16, 2026 07:30AM
Jun 22, 2026 07:02AM
Jun 22, 2026 07:00AM
Jun 8, 2026 08:11AM
Jun 8, 2026 08:10AM
Jun 2, 2026 07:31AM
Jun 2, 2026 07:30AM Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
May 14, 2026 07:31AM
May 14, 2026 07:30AM
May 6, 2026 07:32AM
May 6, 2026 07:30AM
Apr 14, 2026 07:32AM
Apr 14, 2026 07:30AM
Apr 9, 2026 07:30AM Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
Mar 31, 2026 04:15PM
Jan 30, 2026 04:15PM
Jan 30, 2026 04:15PM
Dec 8, 2025 08:32AM
Dec 8, 2025 08:30AM
Dec 4, 2025 08:32AM
Dec 4, 2025 08:30AM Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
Dec 1, 2025 08:30AM
Dec 1, 2025 08:30AM
Nov 26, 2025 08:30AM
Nov 18, 2025 08:30AM
Nov 17, 2025 08:31AM
Nov 17, 2025 08:30AM
Aug 28, 2025 08:00AM Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 25, 2025 07:31AM
Aug 25, 2025 07:30AM
May 27, 2025 08:00AM
May 22, 2025 08:00AM
May 13, 2025 08:00AM
May 6, 2025 07:30AM
Apr 28, 2025 08:00AM Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation
Apr 17, 2025 08:30AM
Apr 15, 2025 08:32AM
Apr 15, 2025 08:30AM
Apr 10, 2025 08:00AM
Apr 2, 2025 04:10PM
Sep 25, 2024 08:01AM
Sep 25, 2024 08:00AM Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Sep 20, 2024 09:00AM

329,957 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All